Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even w
The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnosti
This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for dis